A practical reference on fatty diacid: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-25. Anything still debated is marked as such rather than presented as settled.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
=== Insulin === Insulin is released from the pancreas and into the bloodstream in response to increased glucose concentration in the blood. Insulin is stored in beta cells in the pancreas. When glucose in the blood binds to glucose receptors on the beta cell membrane, a signal cascade is initiated inside the cell that results in insulin stored in vesicles in these cells being released into the blood stream. Increased insulin levels cause the uptake of glucose into the cells. GLUT4 is stored in the cell in transport vesicles, and is quickly incorporated into the plasma membrane of the cell when insulin binds to membrane receptors. Under conditions of low insulin, most GLUT4 is sequestered in intracellular vesicles in muscle and fat cells. As the vesicles fuse with the plasma membrane, GLUT4 transporters are inserted and become available for transporting glucose, and glucose absorption increases. The genetically engineered muscle insulin receptor knock‐out (MIRKO) mouse was designed to be insensitive to glucose uptake caused by insulin, meaning that GLUT4 is absent. Mice with diabetes or fasting hyperglycemia, however, were found to be immune to the negative effects of the insensitivity.
=== Procedure === During the insertion procedure, the provider will first insert a speculum into the vagina to get a good view of the cervix (the opening to the uterus). The provider will then cleanse the cervix. Next, the provider will hold the cervix and provide a gentle outward pull with a tool called a tenaculum, which stabilizes the cervix and straightens out entrance of the uterus (which is typically curved at rest). This increases ease of insertion and helps with proper placement of the IUD. A suction cervical stabilizer can be used in place of the standard tenaculum, and they may reduce pain associated with the insertion procedure. The next step of insertion is measurement of the depth of the uterine cavity with a thin uterine sounding (measuring) device. The provider will then set the measured uterine depth on the IUD insertion device to ensure proper placement. The IUD insertion device will then be inserted through the cervix into the uterus to place the IUD. The procedure itself, if uncomplicated, should take no more than five to ten minutes. For immediate postpartum insertion, the IUD is inserted following delivery of the placenta. After vaginal deliveries, insertions can be done using placental forceps, a longer inserter specialized for postpartum insertions, or manually. After cesarean deliveries, the IUD is placed in the uterus with forceps or manually during surgery before suturing the uterine incision. Generally, the removal is uncomplicated and reported to be not as painful as the insertion because no instrument is inserted through the cervix.
=== Ostwald ripening === Ostwald ripening is a process in which large particles grow at the expense of the smaller particles as a result of dissolution of small particles and deposition of the dissolved molecules on the surfaces of the larger particles. It occurs because smaller particles have a higher surface energy than larger particles. This process is typically undesirable in nanoparticle synthesis as it negatively impacts the functionality of nanoparticles.
=== Works cited === Dorland's Illustrated Medical Dictionary (32nd ed.). Philadelphia, PA: Elsevier / Saunders. 2012. ISBN 978-1-4557-0985-4. Young, Barbara; O'Dowd, Geraldine; Woodford, Phillip (4 November 2013). Wheater's Functional Histology: A Text and Colour Atlas (6th ed.). Philadelphia: Elsevier. ISBN 978-0-7020-4747-3.
=== Criminological profile of the killer === In February 2025, a group of criminologists from the Judicial Police presented a report on the deaths of the babies, assuring that they were a part of "serial criminality", and not accidental or natural deaths. The report stated that the perpetrator had access to the restricted unit of the neonatal unit, where most of the attacks occurred. It also said that the killer had access to medications, with a professional and medical knowledge of the handling of these drugs, and whose presence in the restricted unit would not raise any suspicion, for which their presence was justified. The report concluded that the perpetrator selected "extremely vulnerable" victims who did not pose any resistance, for which they sought the perfect moment to inject an external agent into their bodies with the intent to cause harm and death. Further profiling was presented on 16 February by a medical professor and a social worker. They indicated that the perpetrator would not have stopped killing if they would have been detained. The report further stated that there could have probably been a "cooling period", before undoubtedly continuing to kill.
Sources: en.wikipedia.org
=== Prescribing restrictions === Isotretinoin is a teratogen; there is about a 20–35% risk for congenital defects in infants exposed to the drug in utero, and about 30–60% of children exposed to isotretinoin prenatally have been reported to show neurocognitive impairment. Because of this risk, there are strict controls prescribing isotretinoin to women who have potential to become (or be) pregnant while taking isotretinoin and many are strongly advised to terminate their pregnancies because of the 20-60% risk. Isotretinoin is also not recommended for use by breastfeeding women. In the United States, since March 2006, the dispensing of isotretinoin is run through the iPLEDGE program, under the direction of the Food and Drug Administration. Prescribers, pharmacists, and all people to whom the drug is prescribed need to register on the site and log information into it. Women with child-bearing potential must commit to using two forms of effective contraception simultaneously for the duration of isotretinoin therapy and for a month immediately preceding and a month immediately following therapy. Additionally, they must have two negative pregnancy tests 30 days apart and have negative pregnancy tests before each prescription is written. In most countries, isotretinoin can only be prescribed by dermatologists or specialist physicians; some countries also allow limited prescriptions by general practitioners and family doctors. In the United Kingdom and Australia, isotretinoin may be prescribed only by or under the supervision of a consultant dermatologist.
== Discovery == The discovery of KLB represents an example of a “genome mining” approach. Cluster of genes encoding KLB biosynthetic pathway was found in genome database using low-level homology of one of the proteins to microcin B17 synthetase. Cloning and expression of cluster in a heterologous host (Escherichia coli) yielded the active compound. The name given to the compound reflects the original bacterium where the biosynthetic cluster was found (Klebs-) and the presence of azole cycles (-azolicin).
Peptide-methionine (S)-S-oxide reductase (EC 1.8.4.11, MsrA, methionine sulphoxide reductase A, methionine S-oxide reductase (S-form oxidizing), methionine sulfoxide reductase A, peptide methionine sulfoxide reductase, formerly protein-methionine-S-oxide reductase) is an enzyme with systematic name peptide-L-methionine:thioredoxin-disulfide S-oxidoreductase (L-methionine (S)-S-oxide-forming). This enzyme catalyses the following chemical reaction
Astatine is the rarest naturally occurring element. The total amount of astatine in the Earth's crust (quoted mass 2.36 × 1025 grams) is estimated by some to be less than one gram at any given time. Other sources estimate the amount of ephemeral astatine, present on earth at any given moment, to be up to one ounce (about 28 grams). Any astatine present at the formation of the Earth has long since disappeared; the four naturally occurring isotopes (astatine-215, -217, -218 and -219) are instead continuously produced as a result of the decay of radioactive thorium and uranium ores, and trace quantities of neptunium-237. The landmass of North and South America combined, to a depth of 16 kilometers (10 miles), contains only about one trillion astatine-215 atoms at any given time (around 3.5 × 10−10 grams). Astatine-217 is produced via the radioactive decay of neptunium-237. Primordial remnants of the latter isotope—due to its relatively short half-life of 2.14 million years—are no longer present on Earth. However, trace amounts occur naturally as a product of transmutation reactions in uranium ores. Astatine-218 was the first astatine isotope discovered in nature. Astatine-219, with a half-life of 56 seconds, is the longest lived of the naturally occurring isotopes. Isotopes of astatine are sometimes not listed as naturally occurring because of misconceptions that there are no such isotopes, or discrepancies in the literature. Astatine-216 has been counted as a naturally occurring isotope but reports of its observation (which were described as doubtful) have not been confirmed.
The interaction strength between protein partners should be tunable between a lifetime of seconds (desirable for dynamic signaling events) up to an irreversible interaction (desirable for device stability or resilient to harsh conditions). Interactions such as coiled coils, SH3 domain-peptide binding or SpyTag/SpyCatcher offer such control. In addition, it is necessary to regulate protein-protein interactions in cells, such as with light (using light-oxygen-voltage-sensing domains) or cell-permeable small molecules by chemically induced dimerization. In a living cell, molecular motifs are embedded in a bigger network with upstream and downstream components. These components may alter the signaling capability of the modeling module. In the case of ultrasensitive modules, the sensitivity contribution of a module can differ from the sensitivity that the module sustains in isolation.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.